SELP and COVID-19: Montelukast can effectively suppress inflammation by inhibiting NF-κB activation and the downstream pro-inflammatory cytokines (IL-6, TNF-α, MCP-1, et al.)secretion in cultured human mononuclear cells and macrophages upon stimulation.415,416 In addition, montelukast is also capable of inhibiting platelet activation under the stimulation of serum from COVID-19 patients by downregulating the surface expression of tissue factors and P-selectin.